Navigation Links
Avalon Pharmaceuticals Announces Positive Interim Results For,AVN944 Phase I Trial

e dose escalation trial in patients with advanced hematologic malignancies. Patients are dosed for 21 days on a 28-day cycle. A minimum of three patients are treated at each dose level. The study is divided into two arms, one for treatment of leukemia patients and the other for treatment of patients with lymphoma and myeloma. For the leukemia arm of the study, patients are currently being treated at the tenth dose level, 250 mg twice daily. For the lymphoma and myeloma arm, patients are currently being treated at the sixth dose level, 150 mg twice daily.

Positive Safety and Tolerability Data: The goal of the Phase I study is to establish the safety, tolerability and pharmacokinetics of the drug. Thus far, 104 one-month cycles of AVN944 have been initiated in 46 patients and the compound is well tolerated. Pharmacokinetics measurements indicate dose proportional plasma levels of AVN944 during treatment and sustained plasma concentrations at the dose levels tested thus far.

Early Activity Indicators: This Phase I study is designed to evaluate several pharmacodynamic and efficacy-related endpoints. Upon entering the trial, all patients have refractory, progressive disease and have failed all prior therapies. Thus far, 18 of 39 evaluable patients (46%) showed stabilized disease after one cycle of treatment with AVN944. These include patients with both leukemia and multiple myeloma. Patients who have achieved stable disease following completion of a one-month treatment cycle with AVN944, as determined by the clinical investigator, may be advanced to a subsequent cycle.

In the multiple myeloma cohort 60% of the patients have achieved stabilized disease after one month. Two of these patients completed five months of treatment and two others completed one full year of treatment. One AML patient has completed 8 monthly cycles of treatment.

Positive Dose Dependent Biomarker Data: The AvalonRx(R) platform has identified selected biomarkers from pati
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Avalon Updates the AVN944 Phase I Hematologic Malignancies Trial
2. Avalon Pharmaceuticals to Present at the American Association for Cancer Research 2007 Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:12/19/2014)... Dec. 18, 2014  Sage Analytics ( www.sageanalytics.com ... equipment for the testing of marijuana potency and ... new Luminary™ Profiler, the industry,s first product suite ... a cost-effective, portable unit. Designed from ... of the cannabis industry, the Luminary™ Profiler utilizes ...
(Date:12/19/2014)... INC. (NYSE: RMD ) today announced that it ... on Thursday, January 22, 2015, after the New York Stock ... be issued after 1:00 p.m. US Pacific Time and the ... future outlook. The earnings call is scheduled to ... webcast of the call can be accessed on ResMed,s Investor ...
(Date:12/19/2014)... KANSAS CITY, Kan. , Dec. 18, 2014 ... PETX ), a biopharmaceutical company focused on ... for companion animals, today announced positive results from ... company,s innovative drug for treating pain in dogs ... demonstrated improvements in pain assessment scores that were ...
Breaking Medicine Technology:Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2ResMed To Announce Second Quarter 2015 Results 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5
... Jan. 28 Some 18-20 million Americans are at ... to 10 percent have been diagnosed.  Studies prove that fatality is ... OSA can be readily and successfully treated. , Historically, OSA ... a technician directly monitoring a patient,s breathing.  Many who suspect they ...
... DIEGO , Jan. 28 Conatus Pharmaceuticals Inc. ... evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin ... of the triple combination will be assessed after up to ... medical need in HCV patients who have not responded to ...
Cached Medicine Technology:NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 2NovaSom(R) Diagnostic System Can Assist in Raising Diagnosis Rate for Potentially Lethal Condition 3Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 2Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV) 3
(Date:12/19/2014)... B. E. Smith, the only full-service leadership ... retained to lead a national chief financial officer ... Park, Colo. The top executive search firm in the ... than 900 healthcare executives into organizations. , Estes ... access hospital and level IV trauma center, with a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Hands On Mobile ... available. The Spa On Wheels has been transformed into ... from the outside world seems to disappear. The Virtual Tour ... massages, facials, spa parties, corporate events and more. , The ... Spa On Wheels which is actually an overhauled Winnebago. Marla ...
(Date:12/19/2014)... Slone Partners , a national recruitment firm ... and laboratory testing industries, has promoted Leslie Loveless ... announcement comes after a year of expansion by ... Boston and several new additions to the team. ... experience," said Adam Slone, Chief Executive Officer. “Diagnostics ...
(Date:12/19/2014)... 19, 2014 The Hermitage Club ... in Southern Vermont’s Deerfield Valley, announced today that it ... classic rock songs. , Three time Grammy Award ... private concert followed by a trail naming ceremony. Hermitage ... names include: “I’m Alright” the theme song for the ...
(Date:12/19/2014)... Amy Norton HealthDay ... Children born to moms who were exposed to high levels ... risk of developing autism, a U.S. study suggests. Researchers ... between 1990 and 2002, those exposed to the most air ... baby who later developed autism. And exposure during the third ...
Breaking Medicine News(10 mins):Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Estes Park Medical Center Retains B. E. Smith to Recruit New Chief Financial Officer 3Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3
... , , THURSDAY, Nov. 1 (HealthDay News) -- Heart disease ... for an individual,s brothers or sisters, too, U.S. researchers ... among brothers, the Johns Hopkins University team found. For ... chest pain from blocked arteries, the other is 20 ...
... SACRAMENTO, Calif., Nov. 1 Always Best Care ... California,areas. America,s premier In-Home Care, Assisted Living Placement ... seniors in Granada,Hills/Sherman Oaks can now rely on ... over a decade, a caring relationship has been ...
... Addition to Postal Service Social Awareness Stamp,Series, WASHINGTON, ... next year to help raise awareness about Alzheimer,s disease,as ... John,Potter announced today, on the first day of both ... "With the Alzheimer,s Awareness commemorative stamp, we,ll ask,Americans ...
... the current issue of Clinical Pharmacology & Therapeutics, ... Bioethics and Johns Hopkins Berman Institute of Bioethics ... vaccine debate, and its effects on ethical and ... was a major achievement for cervical cancer prevention ...
... program,s launch, study found , , THURSDAY, Nov. 1 (HealthDay ... Part D prescription drug benefit increased the number of ... $32 billion to Medicare, a new study concludes. , ... Health Affairs , the study authors noted that many ...
... a statement,from ADA President Mark J. Feldman:, "The ... Camp (R-MI) for introducing legislation that will help bring ... tribal areas,where too many people lack sufficient access to ... "The Native American Full Access to Dental Care ...
Cached Medicine News:Health News:Siblings Often Share Heart Risks 2Health News:Siblings Often Share Heart Risks 3Health News:Announcing Always Best Care Senior Services Expansion Into the Granada Hills/Sherman Oaks, California Areas 2Health News:Alzheimer's Disease to be Highlighted on Stamp Next Year 2Health News:A missed shot: The failure of HPV vaccination state requirements 2Health News:A missed shot: The failure of HPV vaccination state requirements 3Health News:Medicare Drug Plan Cost $32 Billion in 2006 2Health News:Medicare Drug Plan Cost $32 Billion in 2006 3Health News:Statement by ADA President Mark J. Feldman on the Native American Full Access to Dental Care Act 2
...
Bimod, acetabular cup "Xl" UHMWHDPE....
Metal on metal hip acetabular cups available for both cemented and cementless applications, the Biomet Merck metal on metal articulation hip system (M2aTM) combines proven materials with the latest i...
S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
Medicine Products: